Male Breast Cancer

To our knowledge, this is only the fourth case of its kind and the only one to provide gross imagery and two separate confirmatory pathology reports. Implications of the findings include continued preferred management via surgical excision, remaining awareness of rare tumors, and additional evidence for the possible prevalence of rare male breast tumors that may have been previously not considered.

Our findings suggest a unique genomic and immunologic landscape in MaBC requiring a sex-informed approach and provide candidate therapeutic targets and mechanisms of resistance.

Although drug therapy and radiation therapy were recommended after the operation, the patient was under observation due to his advanced age. A brief literature review is presented in this section.

As the inaugural germline genomic investigation of MaBC in a Han Chinese population, this work reveals clinically actionable alterations with diagnostic and therapeutic implications. These discoveries not only advance our understanding of MaBC's molecular architecture but also underscore the critical need for dedicated research into this malignancy.

Management strategies for male breast cancer generally parallel female protocols, despite unique biological features. By integrating considerations of benign and malignant conditions, this review underscores the importance of tailored evaluation, risk assessment, and individualized care for males, while identifying knowledge gaps to inform future research and improve outcomes in this under-recognized population.

Oncotype diagnosis (DX) testing indicated a low chemotherapy benefit, leading to adjuvant therapy with tamoxifen...The prompt detection of the suspicious mass, culminating in effective early-stage treatment, proved crucial to this patient's favorable prognosis, in contrast to the common trend of delayed diagnoses and their less promising outcomes. Accordingly, strengthening public awareness and professional training is essential to optimize management and improve outcomes in men with breast cancer.

Median overall survival (OS) 131 months (1-, 2-, 5-, 10-year OS: 95%, 93%, 73%, 53%). This long-term cohort highlights the predominance of hormone-receptor positivity, the infrequency of germline mutations, and moderate survival rates, informing patient management and guiding future studies.

It accurately separated patients with good, intermediate, and poor performance at high statistical significance. Development of a MBC-specific prediction tool remains desirable.

This case suggests that CDK4/6 inhibitor-based endocrine therapy can induce meaningful disease reversal even in visceral crisis and may be a feasible option for selected HR+/HER2- MBC patients after chemotherapy failure. Our case suggests that CDK4/6 inhibitor-based endocrine therapy may offer clinical benefit even in the setting of visceral crisis after chemotherapy failure, indicating that treatment sequencing in such scenarios may merit further consideration.

Treatment principles for MBC mirror those of female breast cancer and include mastectomy, endocrine therapy (tamoxifen), radiotherapy, and systemic therapy as indicated...This case highlights the rarity of EPC with a mixed invasive component in men and underscores the importance of comprehensive morphologic and immunophenotypic evaluation. Increased reporting of such cases will improve understanding and management of male breast malignancies.

We concluded that MBC and FBC exhibit both genomic similarities and distinctions in our study. In the context of precision medicine, this study may provide new ideas and a basis for the diagnosis and treatment of MBC.

Pathologists and clinicians should be aware that although pilomatricoma is a common skin adnexal tumour in the head and neck region, it can rarely present as a breast lump. Recognising this uncommon presentation is essential to avoid misdiagnosis and ensure appropriate management.